Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Histone H2AX promotes neuronal health by controlling mitochondrial homeostasis.

Weyemi U, Paul BD, Bhattacharya D, Malla AP, Boufraqech M, Harraz MM, Bonner WM, Snyder SH.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7471-7476. doi: 10.1073/pnas.1820245116. Epub 2019 Mar 25.

PMID:
30910969
2.

Histone H2AX deficiency causes neurobehavioral deficits and impaired redox homeostasis.

Weyemi U, Paul BD, Snowman AM, Jailwala P, Nussenzweig A, Bonner WM, Snyder SH.

Nat Commun. 2018 Apr 18;9(1):1526. doi: 10.1038/s41467-018-03948-9.

3.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

4.

Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions.

Kim J, Sturgill D, Sebastian R, Khurana S, Tran AD, Edwards GB, Kruswick A, Burkett S, Hosogane EK, Hannon WW, Weyemi U, Bonner WM, Luger K, Oberdoerffer P.

Mol Cell. 2018 Jan 4;69(1):36-47.e7. doi: 10.1016/j.molcel.2017.11.021. Epub 2017 Dec 14.

5.

Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression.

Contrepois K, Coudereau C, Benayoun BA, Schuler N, Roux PF, Bischof O, Courbeyrette R, Carvalho C, Thuret JY, Ma Z, Derbois C, Nevers MC, Volland H, Redon CE, Bonner WM, Deleuze JF, Wiel C, Bernard D, Snyder MP, RĂ¼be CE, Olaso R, Fenaille F, Mann C.

Nat Commun. 2017 May 10;8:14995. doi: 10.1038/ncomms14995.

6.

p21: A Two-Faced Genome Guardian.

Georgakilas AG, Martin OA, Bonner WM.

Trends Mol Med. 2017 Apr;23(4):310-319. doi: 10.1016/j.molmed.2017.02.001. Epub 2017 Mar 7. Review.

PMID:
28279624
7.

The Causal Relationship between DNA Damage Induction in Bovine Lymphocytes and the Fukushima Nuclear Power Plant Accident.

Nakamura AJ, Suzuki M, Redon CE, Kuwahara Y, Yamashiro H, Abe Y, Takahashi S, Fukuda T, Isogai E, Bonner WM, Fukumoto M.

Radiat Res. 2017 May;187(5):630-636. doi: 10.1667/RR14630.1. Epub 2017 Feb 27.

8.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM.

PLoS One. 2017 Feb 3;12(2):e0171582. doi: 10.1371/journal.pone.0171582. eCollection 2017.

9.

Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model.

Parekh PR, Choudhuri R, Weyemi U, Martin OA, Bonner WM, Redon CE.

Cancer Med. 2016 Aug;5(8):1731-41. doi: 10.1002/cam4.726. Epub 2016 Jun 23.

10.

Twist1 and Slug mediate H2AX-regulated epithelial-mesenchymal transition in breast cells.

Weyemi U, Redon CE, Sethi TK, Burrell AS, Jailwala P, Kasoji M, Abrams N, Merchant A, Bonner WM.

Cell Cycle. 2016 Sep 16;15(18):2398-404. doi: 10.1080/15384101.2016.1198864. Epub 2016 Jun 17.

11.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH.

Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11.

12.

Effects of Breast Shielding during Heart Imaging on DNA Double-Strand-Break Levels: A Prospective Randomized Controlled Trial.

Cheezum MK, Redon CE, Burrell AS, Kaviratne AS, Bindeman J, Maeda D, Balmakhtar H, Pezel A, Wisniewski P, Delacruz P, Nguyen B, Bonner WM, Villines TC.

Radiology. 2016 Oct;281(1):62-71. doi: 10.1148/radiol.2016152301. Epub 2016 Apr 15.

13.

H2AX and EMT: deciphering beyond DNA repair.

Weyemi U, Redon CE, Bonner WM.

Cell Cycle. 2016 May 18;15(10):1305-6. doi: 10.1080/15384101.2016.1160659. Epub 2016 Mar 17. No abstract available.

14.

The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition.

Weyemi U, Redon CE, Choudhuri R, Aziz T, Maeda D, Boufraqech M, Parekh PR, Sethi TK, Kasoji M, Abrams N, Merchant A, Rajapakse VN, Bonner WM.

Nat Commun. 2016 Feb 15;7:10711. doi: 10.1038/ncomms10711.

15.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

16.

Evidence for chromosome fragility at the frataxin locus in Friedreich ataxia.

Kumari D, Hayward B, Nakamura AJ, Bonner WM, Usdin K.

Mutat Res. 2015 Nov;781:14-21. doi: 10.1016/j.mrfmmm.2015.08.007. Epub 2015 Aug 30.

17.

Inactivation of NADPH oxidases NOX4 and NOX5 protects human primary fibroblasts from ionizing radiation-induced DNA damage.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Radiat Res. 2015 Mar;183(3):262-70. doi: 10.1667/RR13799.1. Epub 2015 Feb 23.

18.

NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2121-6. doi: 10.1073/pnas.1418139112. Epub 2015 Feb 2.

19.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

20.

Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.

Georgakilas AG, Redon CE, Ferguson NF, Kryston TB, Parekh P, Dickey JS, Nakamura AJ, Mitchell JB, Bonner WM, Martin OA.

Cancer Lett. 2014 Oct 28;353(2):248-57. doi: 10.1016/j.canlet.2014.07.030. Epub 2014 Jul 25.

Supplemental Content

Loading ...
Support Center